The Medical Letter on Drugs and Therapeutics
In Brief: Meningococcal Prophylaxis
Download PDF:   US English
Med Lett Drugs Ther. 2008 Apr 7;50(1283):25
 Select a term to see related articles  2008   April 7   azithromycin   ceftriaxone   Cipro   Ciprofloxacin   Fluoroquinolone resistance   In brief   Issue 1283   Meningococcal prophylaxis   Meningococcal vaccines   Neisseria meningitidis   page 25   Rifadin   Rifampin   Rocephin   vaccines   volume 50   Zithromax 

The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines (Med Lett Drugs Ther 2005; 47:29) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread.

A single oral dose of ciprofloxacin (Cipro, and others) 500 mg has been used for prophylaxis after close contact with infected patients. Oral rifampin (Rifadin, and others) 600 mg (10 mg/kg for children) q12h for 2 days, a single IM injection of ceftriaxone (Rocephin, and others) 250 mg (125 mg for children), or a single oral dose of azithromycin (Zithromax, and others) 500 mg (10 mg/kg for children) are reasonable alternatives.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article